Abstract for Orviglance comparison study to gadolinium accepted at the world’s largest radiology conference RSNA

2021-08-13
Download

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the study where Orviglance® (manganese chloride tetrahydrate, former working name Mangoral) was compared against a gadolinium-based specific contrast agent has been accepted as an oral paper presentation at the world’s largest radiology conference RSNA. The conference will be held November 28 – December 3 in Chicago, Illinois.

In December 2020, Ascelia Pharma announced the results of a comparison study versus a gadolinium contrast agent. The results showed that Orviglance enhanced MRI was as effective as the gadolinium contrast agent gadobenate dimeglumine (Multihance) in terms of visualization of lesions and number of detected lesions detection. In fact, 2 out of the 3 independent readers reported higher scores for Orviglance enhanced MRI. The results also showed that Orviglance enhanced MRI provides improved diagnostic efficacy compared to MRI without a contrast agent using identical endpoints as in the ongoing pivotal Phase 3 study SPARKLE.

“We are very pleased that the study has been selected as an oral paper presentation at the prestigious radiology conference RSNA. The study provides a robust evidence of the diagnostic value that Orviglance can offer once available to patients and physicians. Orviglance is being developed to address the unmet medical need of patients with poor kidney function, and it is encouraging that Orviglance* is as effective as a gadolinium contrast agent, said Carl Bjartmar, Chief Medical Officer at Ascelia Pharma.
 
*Trademark is registered in Europe and several other markets and submitted for registration in the US.

2021-09-21

Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF®

Ascelia Pharma AB (publ) (ticker: ACE) today announced that it has signed a clinical collaboration agreement with Taiho Oncology Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. The collaboration concerns an upcoming global Phase 2 clinical study in gastric cancer. In this all-oral combination study, Ascelia Pharma’s irinotecan chemotherapy tablet Oncoral (ASC-201) will be evaluated in combination with Taiho Oncology’s LONSURF® (trifluri ...
2021-08-19

Quarterly Report Q2 2021: Preparing Oncoral for the next level

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q2 2021 (April – June 2021), which is now available on the company’s website: https://www.ascelia.com/ir-media/reports-presentations/
2021-08-18

Covid-19 extends recruitment period of SPARKLE study

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the continued global impact of the Covid-19 pandemic could extend the recruitment period of the clinical phase 3 study SPARKLE with up to 6 months. The recruitment is now expected to be completed during H1 2022. Ascelia Pharma has a solid cash position supporting operations well into 2023.